CONMED (CNMD)
(Delayed Data from NYSE)
$71.00 USD
+0.40 (0.57%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $71.01 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNMD 71.00 +0.40(0.57%)
Will CNMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CNMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNMD
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
Henry Schein (HSIC) Down 4.3% Since Last Earnings Report: Can It Rebound?
Merit Medical (MMSI) Up 5% Since Last Earnings Report: Can It Continue?
Other News for CNMD
CONMED Corporation to Announce Second Quarter 2024 Financial Results on July 31, 2024
AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation
Clearmind secures exclusive rights to potential PSTD therapies
Warning: CNMD is at high risk of performing badly
Conmed Announces Executive Transition and New Officer Compensation